Alectinib
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID92548
CAS NO.1256580-46-7
Purity 98%
MDL NumberMFCD19440988
Molecular Formula C30H34N4O2
Molecular Weight 482.617
| Category | Content |
|---|---|
| Generic Name | Alectinib |
| Brand Name | ALECENSA |
| Chemical Formula | C30H34N4O2·HCl |
| CAS Number | 1383516-62-8 |
| Mechanism of Action | Alectinib is a potent and selective ALK tyrosine kinase inhibitor that targets ALK and RET. It inhibits ALK phosphorylation and downstream signaling pathways, reducing tumor cell viability. |
| Indications | – Indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.<br>- Used in patients who have progressed on or are intolerant to crizotinib. |
| Dosage Forms | Capsules (150 mg) |
| Administration | – Recommended dose: 600 mg orally twice daily with food.<br>- For severe hepatic impairment (Child-Pugh C): 450 mg orally twice daily. |
| Pharmacokinetics | – High bioavailability when taken with food.<br>- Half-life: Approximately 33 hours.<br>- Metabolized primarily by CYP3A4. |
| Side Effects | – Common: Constipation, edema, myalgia, fatigue.<br>- Serious: Hepatotoxicity, interstitial lung disease/pneumonitis, bradycardia, elevated CPK levels. |
| Precautions | – Monitor liver function tests regularly.<br>- Use with caution in patients with severe hepatic impairment.<br>- Advise females of reproductive potential to use effective contraception. |
| Storage | Store at room temperature, protect from moisture. |
| Developer | Genentech, Inc. |
| Approval Date | FDA approval in 2015. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
